Bioelectronics startup Neuspera nets $26M in two-tranche series B

Cash register full of money
The second and final $12 million tranche was triggered after the company met development and regulatory objectives, according to the company. (Michael Burrell/iStock/Getty Images Plus)

Neuspera Medical has raised a new total of $26 million in equity financing, following the closing of the second tranche of its series B round, to help fund clinical testing programs for its neuromodulation implants.

Each of the round’s original investors returned to participate, including 6 Dimensions Capital, Action Potential Venture Capital, Windham Venture Partners, Delta Capital, Purple Arch Ventures and others.

The second and final $12 million tranche was triggered after the company met development and regulatory objectives, the San Jose, California-based company said in a statement. The series B round first closed in January 2018.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Neuspera is focused on developing techniques to transfer power to implants from outside the body, using electromagnetic waves—to allow for smaller, sealed implant designs, compared to battery-powered neuromodulation devices. The company was first founded in 2014 as Vivonda Medical.

RELATED: Electroceuticals startup NeuSpera raises $8M to back tiny, injectable neuromodulation tech

The company believes it can use the structure of the human body to help guide and focus electromagnetic waves, in order to power implants located deeper in muscle and bone, while maintaining a device smaller than a few millimeters in size.

The implanted electrical stimulators can then help maintain heartbeats or treat neurological diseases, as well as help power other devices, Neuspera said.

Suggested Articles

Novocure’s tumor-treating electric field system scored an FDA nod in mesothelioma, making it the first new treatment in more than 15 years.

FLX Bio is renaming itself RAPT Therapeutics to reflect its expansion into allergy and inflammatory diseases.

The preclinical-stage biotech wants the cash to take an antisense oligonucleotide treatment for Dravet syndrome through to phase 3.